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Multiplex ligation-dependent probe amplification (MLPA) is a recently described method for detecting gross deletions or duplications
of DNA sequences, aberrations which are commonly overlooked by standard diagnostic analysis. To determine the incidence of copy
number variants in cancer predisposition genes from families in the Wessex region, we have analysed the hMLH1 and hMSH2 genes
in patients with hereditary nonpolyposis colorectal cancer (HNPCC), BRCA1 and BRCA2 in families with hereditary breast/ovarian
cancer (BRCA) and APC in patients with familial adenomatous polyposis coli (FAP). Hereditary nonpolyposis colorectal cancer
(n¼162) and FAP (n¼74) probands were fully screened for small mutations, and cases for which no causative abnormality were
found (HNPCC, n¼122; FAP, n¼24) were screened by MLPA. Complete or partial gene deletions were identified in seven cases
for hMSH2 (5.7% of mutation-negative HNPCC; 4.3% of all HNPCC), no cases for hMLH1 and six cases for APC (25% of mutation
negative FAP; 8% of all FAP). For BRCA1 and BRCA2, a partial mutation screen was performed and 136 mutation-negative cases were
selected for MLPA. Five deletions and one duplication were found for BRCA1 (4.4% of mutation-negative BRCA cases) and one
deletion for BRCA2 (0.7% of mutation-negative BRCA cases). Cost analysis indicates it is marginally more cost effective to perform
MLPA prior to point mutation screening, but the main advantage gained by prescreening is a greatly reduced reporting time for the
patients who are positive. These data demonstrate that dosage analysis is an essential component of genetic screening for cancer
predisposition genes.
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Multiplex ligation-dependent probe amplification (MLPA) is a
new, high-resolution method for detecting copy number variations
in genomic sequences (Schouten et al, 2002). Available evidence
suggests that MLPA is a robust assay, which offers several
advantages over existing techniques (Taylor et al, 2003).
Many diagnostic genetics laboratories are therefore adopting
MLPA for analysis of genes such as hMLH1, hMSH2, BRCA1,
BRCA2 and APC in preference to other techniques, for example,
those based on quantitative-fluorescent PCR (QF-PCR) or
multiple amplifiable probe hybridisation (MAPH). Laboratories
have to decide whether dosage analysis should be performed
before or after point mutation analysis, a decision that depends
in part on the frequency of copy number variants in the local
population.
Copy number variants in cancer predisposition genes are found
at a frequency of around 4–15% in most countries, although
founder effects have been reported in some study populations
(Petrij-Bosch et al, 1997; Wagner et al, 2003). Previous studies of
hereditary nonpolyposis colorectal cancer (HNPCC) patients using
QF-PCR or Southern blotting have detected hMLH1 and hMSH2
copy number variants in 5% of probands in Germany (Wang et al,
2003), 5% in Japan (Nakagawa et al, 2003), 15% in France
(Charbonnier et al, 2002) and 27% in the USA (Wagner et al,
2003). Two analyses using MLPA have reported hMLH1 and
hMSH2 copy number variants in 13% of families from Holland
(Gille et al, 2002) and 6% from the North of England (Taylor et al,
2003). Multiplex ligation-dependent probe amplification studies of
breast/ovarian cancer patients have given similar figures with 14%
of Italian probands (Montagna et al, 2003) and 4% of Dutch
probands (Hogervorst et al, 2003) having a dosage variant of the
BRCA1 gene. One published study of familial adenomatous
polyposis coli (FAP) patients using QF-PCR detected large
deletions of APC in 12% of classical polyposis patients (Sieber
et al, 2002).
With such a significant detection rate of copy number variants,
it is clearly important to decide whether MLPA should be
employed before or after standard mutation analysis. We present
here an analysis of the frequency of copy number variants in
HNPCC, FAP and hereditary breast/ovarian cancer from the
Wessex region of the UK (which has a population of approximately
3 million people) and compare the relative testing cost and waiting
times for prospective vs retrospective MLPA screening. Received 26 March 2004; revised 5 July 2004; accepted 6 July 2004
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HNPCC cohort
During the 8-year period 1995–2003, a total of 162 probands
referred for suspected HNPCC from the Wessex region were
collected and screened for point mutations, microdeletions or
microinsertions of the hMLH1 and hMSH2 genes using single-
stranded conformation polymorphism (SSCP) heteroduplex ana-
lysis or, more recently, denaturing high-performance liquid
chromotography (dHPLC) followed by direct sequencing of
abnormal fragments. In all, 50 of these patients fulfilled the
Amsterdam criteria for HNPCC, that is, three relatives with
colorectal cancer (CRC), one of whom is a first-degree relative of
the other two; CRC involving at least two generations; one or more
CRC cases diagnosed before the age of 50 years. A causative
mutation, that is, a premature stop codon, frameshift, splice
recognition site change or amino-acid change that is known to
compromise function, was found in a total of 40 patients (24.7%),
of whom 24 fulfilled the stringent Amsterdam criteria (48% of
Amsterdam-positive patients) and 16 were patients who fulfilled
one or more of the less stringent Bethesda Criteria (14% of patients
not fulfilling the Amsterdam Criteria). The 122 patients in whom
no mutation had been found were subsequently analysed by
MLPA.
Hereditary breast/ovarian cancer cohort
Over the 6-year period 1997–2003, we performed a partial BRCA1
and BRCA2 screen on 679 probands. All patients were tested using
the protein truncation test (PTT) to look for frameshift or
nonsense mutations in exon 11 of both BRCA1 and BRCA2 and
by SSCP or dHPLC followed by sequencing of aberrant fragments
for BRCA1 exons 2 and 20 plus BRCA2 exon 10. This partial screen
covers approximately 65 and 55% of the BRCA1 and BRCA2 coding
sequences, respectively, and a causative mutation was found in 99
patients (15%). All pedigrees were reviewed and ranked in order of
likelihood for an underlying BRCA1 or BRCA2 mutation using the
recently developed Manchester scoring system (Evans et al, 2004).
In brief, each breast or ovarian cancer scores according to the age
at onset and cancer site (ovarian cancer scores higher than breast
cancer), with a small additional score for prostate and pancreatic
cancers in BRCA2. A score of 10 or more equates to at least a 15%
chance of a mutation being detected, the higher the crude score,
the higher the likelihood. In all, 259 samples scoring 10 or above
had been partly or wholly analysed in our laboratory previously
and 83 mutations had been detected (32%). In order to assess the
usefulness of BRCA1 and BRCA2 MLPA, we analysed 136 cases
selected from this group where DNA was available for further
analysis and in which no mutation had been found in the previous
screen.
FAP cohort
During the 11-year period 1992–2003, a total of 74 FAP probands
from the Wessex region were collected and screened for point
mutations, microdeletions or microinsertions of the APC gene
using SSCP or dHPLC followed by direct sequencing of abnormal
fragments. A causative mutation was found in a total of 50 patients
(68%). The 24 patients in whom no mutation had been found were
subsequently analysed by MLPA.
Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification analysis was
performed using kits from MRC-Holland (Amsterdam, The
Netherlands). The kits include probes for each exon of the gene
in question (except BRCA2 exons 5, 6, 23 and 26), probes for a
number of control regions across the genome, plus further controls
to check for adequate quality of test DNA and efficient ligation.
The only alteration to the manufacturer’s protocol was that 1mlo f
DNA was used per MLPA reaction (typically 400–600ng) rather
than the suggested 100ng of DNA. Multiplex ligation-dependent
probe amplification PCR products were separated on an ABI3100
genetic analyser and interpreted using Genotyper version 2.0. Peak
heights from each patient were then exported to an Excel
spreadsheet, which was designed to assess the ratios of each test
peak relative to all other peaks for that individual. Ratios of test
peaks to control peaks and control peaks to other control peaks in
each patient sample were compared to the same ratios obtained for
two normal individuals, which were included in each run. For
normal sequences, a dosage quotient of 1.0 is expected; if a
deletion or duplication is present, the dosage quotient should be
0.5 and 1.5, respectively. In a series of control experiments, we
found that normal sequences gave a mean dosage quotient of 1.04
(range 0.79–1.27, standard deviation¼0.06, n¼143), deleted
sequences gave a mean dosage quotient of 0.50 (range 0.34–0.67,
standard deviation¼0.07, n¼110) and duplicated sequences gave
a mean dosage quotient of 1.60 (range 1.32–1.73, standard
deviation¼0.06, n¼60). Results were deemed acceptable if the
dosage quotient for each control peak fell within the range 0.8–1.2.
A deletion was scored if the mean dosage quotient of the test to
internal control peaks was less than 0.7, and a duplication was
scored if the mean dosage quotient was 1.3 or greater. Intermediate
results were discounted and samples were repeated if the scores
did not fall into the above three categories. In all cases
(approximately 5% of samples), we were able to obtain a
satisfactory result on repeat analysis sometimes by reducing or
increasing the amount of input DNA. Deletions of multiple
contiguous exons are extremely unlikely to have arisen as false
positives by chance in the MLPA assay (Taylor et al, 2003), and
thus we did not confirm these independently. Apparent deletions
of a single exon, however, do need confirmation (Taylor et al,
2003) and so we first checked the sequence of the exon in question
to see if a point mutation or microdeletion/microinsertion was
present that might interfere with MLPA probe hybridisation. If the
sequence was normal, the deletion was confirmed by MAPH or QF-
PCR. In this series, we did not observe any false-positive results,
that is, all single-exon abnormalities detected by MLPA turned out
to be real copy number changes or due to exonic mutations. A
typical MLPA result is shown in Figure 1.
120
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APC Gene deleted exons 7−15
140 160 180 200 220 240 260
7 89 10 11 12 13 14 15 15
280 300 320 340 360 380 400
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Figure 1 An example of the genotyper output from a patient with a deletion of exons 7–15 of the APC gene when compared to a normal individual.
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PCR products were run on a WAV-3500 Transgenomic WAVEt
machine with Navigator v1.5. 2 software and WAVE Optimizedt
Buffers (Transgenomic Inc., Crewe, UK). PCR product (8ml) was
injected at column temperatures selected using the Navigator
melting algorithm software. In general, PCR primers (sequences
available on request) were chosen to include at least 40–50bp of
flanking intron sequence for each exon. Protein truncation test
analysis was performed using the standard method and primer
sequences published by Plummer et al (1995).
Sequencing analysis
Relevant PCR products were sequenced in both forward and
reverse directions using BigDye
s Terminator v1.1. or v3.1
chemistry (Applied Biosystems). Samples underwent 25 cycles of
amplification (30s at 961C, 15s at 501C and 2min at 601C). Excess
terminators were removed using DyeExt 2.0 spin columns
(Qiagen) prior to running on an ABI 3100 genetic analyser.
Costings
Reagent cost calculations (rounded to the nearest pound) were
calculated per sample and are based on standard operational
procedures employed at the Wessex Regional Genetics Laboratory,
average referral rates per annum, average detection rates per gene
and reagent list prices as at December 2003. Reagent costs for
hMLH1 and hMSH2 (full mutation screen and sequence con-
firmation)¼d56; BRCA1/2 (PTT plus full mutation screen and
sequence confirmation) d116; APC (full mutation screen and
sequence confirmation)¼d62; and MLPA¼d7.
To calculate staff costs, we have used an approximate wage
estimate of d10h
 1 (equivalent to an annual wage of d19500) and
an average hands-on time of 2h for MLPA, 13h for PTT plus the
limited BRCA1/2 screen, 52.5h for dHPLC analysis plus sequen-
cing for HNPCC, an estimated 39h for dHPLC analysis plus
sequencing for a full BRCA1/2 screen and 30h for dHPLC analysis
plus sequencing for FAP. Reporting time calculations were based
on a mean reporting time of 5 days for MLPA, 50 days for PTT and
90 days for dHPLC plus sequencing.
RESULTS
Hereditary nonpolyposis colorectal cancer
Using MLPA, we found a deletion of one or more exons of the
hMSH2 gene in seven of the 122 HNPCC patients in whom no
causative mutation had been detected previously (see Table 1).
This equates to 4.3% of all HNPCC probands or 5.7% of probands
without a known causative mutation. Four of these mutations were
found in Amsterdam-positive patients (8% of all Amsterdam-
positive patients; 3.3% of previously mutation-negative probands)
and three were Amsterdam-negative patients (2.7% of all
Amsterdam-negative patients; 2.5% of previously mutation-nega-
tive probands). One patient had a deletion of just exon 1 of the
hMSH2 gene and this was confirmed by a separate laboratory using
MAPH (data not shown). No copy number changes were detected
in the hMLH1 gene.
Breast/ovarian cancer
Of the 136 patients analysed, six copy number variants were found
within the BRCA1 gene and one copy number variant was found
for BRCA2 (5.1%. of cases that were tested and were negative in the
partial mutation screen). The mutations are listed in Table 1. The
individual (BRCA1 #1) with a deletion of BRCA1 exon 20 only was
confirmed in another laboratory using QF-PCR (data not shown);
all the other deletions or duplications involved contiguous exons.
In addition to these cases, MLPA detected apparent single-exon
deletions in two breast cancer patients who were subsequently
shown to have microdeletions within the MLPA probe recognition
sequences: 364delT in BRCA1 exon 6 and 983delACAG in BRCA2
exon 9. These microdeletions prevented the efficient ligation of the
MLPA probes, resulting in an apparent deletion of the whole exon.
Since these mutations would have been picked up by the full
mutation screens that are currently being implemented by NHS
diagnostic laboratories, we did not score them as additional
MLPA-detectable pathogenetic lesions in our analysis.
FAP patients
Multiplex ligation-dependent probe amplification analysis of the
24 previously mutation-negative patients detected a gross deletion
in six individuals (see Table 1), equating to 8% of all patients or
25% of patients in whom no mutation had previously been found.
Costings
The calculations of reagent costs and staff wages are shown in
Table 2 for the different scenarios depending upon sample
category and the initial mutation detection method of choice.
Overheads, equipment costs and depreciation are not included. All
calculations are based on our current annual referral rate for each
syndrome (HNPCC, n¼24; breast cancer, n¼94; FAP, n¼7). The
final estimated costs are not simply the sum of the component tests
due to the sequential nature of the analysis, for example, if MLPA
is performed as a prescreen then those individuals who are positive
will not be subject to the full mutation screen. Similarly, BRCA
patients for whom mutations were identified by PTT would not be
subject to further analysis, except for sequence confirmation.
For HNPCC, prescreening with MLPA results in a saving of d17
per sample for all referrals (d35 for Amsterdam-positive patients).
This equates to a total financial saving per year of d408, if MLPA is
the first mutation detection method used. For breast cancer
patients, MLPA prescreening results in a saving of d22 per patient,
a total of d2016 per year. For FAP, a saving of d6 per person can be
made, a total of d49 per year.
Table 1 Mutations detected by MLPA in the Wessex cancer cohorts
Gene Mutation detected
hMSH2 #1 Deleted exon 1
hMSH2 #2 Deleted exons 1–2
hMSH2 #3 Deleted exons 1–8
hMSH2 #4 Deleted exons 4–16
hMSH2 #5 Deleted exons 9–16
hMSH2 #6 Deleted exons 9–16
hMSH2 #7 Whole gene deletion
BRCA1 #1 Deleted exon 20
BRCA1 #2 Deleted exons 9–12
BRCA1 #3 Deleted exons 21–24
BRCA1 #4 Deleted exons 1–17
BRCA1 #5 Deleted exons 8–13
BRCA1 #6 Duplicated exons 3–5
BRCA2 #1 Deleted exons 1–2
APC #1 Deleted exons 4–15
APC #2 Deleted exons 7–15
APC #3 Whole gene deletion
APC #4 Whole gene deletion
APC #5 Whole gene deletion
APC #6 Whole gene deletion
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A comparison of the average reporting times (see Table 2) shows
that a saving of 3 days can be obtained by prescreening all HNPCC
referrals with MLPA, increasing to 5 days if testing Amsterdam-
positive patients only. Although 3–6 days appears to be a minimal
saving overall, each patient with an MLPA-detectable abnormality
would be reported within 7 days, 81–116 days earlier than the
average reporting time (Table 2). For breast cancer patients, an
average of 6 days can be saved by prescreening with MLPA, and for
FAP patients this figure is 3 days.
DISCUSSION
Multiplex ligation-dependent probe amplification has rapidly
gained acceptance in genetic diagnostic laboratories due to its
simplicity, relatively low cost, capacity for reasonably high
throughput and robustness (Di Fiore et al, 2004). Using MLPA,
we have identified copy number variants at a frequency of 5–8% in
cancer predisposition genes from families in the Wessex region.
Although this is a relatively small proportion of all cases, it does
represent a significant increase in the number of families for whom
a causative mutation can be identified, and thus an increased
number of individuals who will benefit from appropriate counsel-
ling and management. In our series, standard point mutation
analysis enabled causative mutations to be identified in 25% of
HNPCC families, 32% of BRCA families (partial mutation screen
only) with a Manchester score of X10 and 68% of FAP families.
With the incorporation of MLPA in addition to point mutation
screening, causative mutations were identified in 29% of HNPCC
families, 37% of high-risk breast cancer families and 76% of FAP
families.
Considering the nature of the copy number variants, we
identified some features that deserve comment. First, for HNPCC
we found seven copy number variants for hMSH2 but none for
hMLH1. This is in contrast to another study from the UK in which
copy number variants were seen in both genes, although the
overall frequency of variants was similar in both studies (Taylor
et al, 2003). Second, copy number variants were more common for
BRCA1 (n¼6) compared to BRCA2 (n¼1). Finally, four of six
APC variants in apparently unrelated individuals involved the loss
of the whole gene. Although we have not shown that these
abnormalities are the same at the molecular level, they may be
indicative of a local founder effect.
As expected, the proportion of HNPCC copy number variants
was higher in individuals who were Amsterdam positive (8%)
compared to those who were Amsterdam negative (2.7%). One
unexpected benefit from this study was the detection of two small
mutations at the probe binding sites (1 and 4bp deletions) by
MLPA. Although we did not score these changes as new MLPA-
detectable pathogenetic lesions in our analysis, these results
demonstrate that MLPA may be used to detect small mutations
in addition to gross copy number changes.
The cost calculations presented here show that a modest total
financial saving of around d2500 per year may be obtained by
choosing MLPA as the initial mutation screening method for all
hereditary cancer referrals (for a region with a population of 3
million people), as well as the additional advantage of quicker
reporting times for positive individuals. The number of individuals
who would benefit from the shorter reporting time equates to
approximately 150–200 cases per annum in the UK.
Overall our data highlight the fact that dosage analysis is an
essential tool in cancer diagnostics that should be undertaken by
all laboratories, that screen for mutations in cancer predisposition
genes. We have also shown that it is more appropriate to perform
MLPA analysis prior to, rather than after, point mutation analysis
and that reporting times can be substantially reduced for a
proportion of affected individuals.
ACKNOWLEDGEMENTS
We thank Dr John Armour (Institute of Genetics, University of
Nottingham) for MAPH confirmation of the hMSH2 exon 1
deletion case and Dr Catherine Roberts (Northern Molecular
Genetics Diagnostic Service, Newcastle) for QF-PCR confirmation
of the BRCA1 exon 20 deletion case.
REFERENCES
Charbonnier F, Olschwang S, Wang Q, Boisson C, Martin C, Buisine MP,
Puisieux A, Frebourg T (2002) MSH2 in contrast to MLH1 and MSH6 is
frequently inactivated by exonic and promoter rearrangements in
hereditary nonpolyposis colorectal cancer. Cancer Res 62: 848–853
Di Fiore F, Charbonnier F, Martin C, Frerot S, Olschwang S, Wang Q,
Boisson C, Buisine M-P, Nilbert M, Lindblom A, Frebourg T (2004)
Screening for genomic rearrangements of the MMR genes must be
included in the routine diagnosis of HNPCC. J Med Genet 41: 18–20
Table 2 Reagent costs, staff wages (in pounds sterling; overheads and equipment costs not included) and average reporting times per sample depending
on whether MLPA is carried out as a prescreen or a postscreen
Category Testing order Reagent cost (£)
a Staff time (£) Total (£) Average reporting time (days)
All HNPCC MLPA prescreen 61 523 584 91
b
All HNPCC MLPA postscreen 61 540 601 94
Amsterdam-positive HNPCC MLPA prescreen 58 501 559 88
b
Amsterdam-positive HNPCC MLPA postscreen 59 535 594 93
Breast cancer (full screen) MLPA prescreen 107 470 577 123
b
Breast cancer (full screen) MLPA postscreen 113 486 599 129
FAP MLPA prescreen 65 292 357 89
b
FAP MLPA postscreen 64 299 363 92
MLPA¼multiplex ligation-dependent probe amplification; HNPCC¼hereditary nonpolyposis colorectal cancer; FAP¼familial adenomatous polyposis coli.
aIncluding cost of
MLPA @ d7/sample.
bReporting time within 7 days for those cases with an MLPA-detectable copy number change.
Dosage analysis of cancer predisposition genes by MLPA
DJ Bunyan et al
1158
British Journal of Cancer (2004) 91(6), 1155–1159 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sEvans G, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A,
Howell A, Lalloo F (2004) A new scoring system for the chances of
identifying a BRCA1/2 mutation, outperforms existing models including
BRCAPRO. J Med Genet 41: 474–480
Gille JJ, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ,
Meijer GA, Craanen ME, Nederlof PM, de Jong D, McElgunn CJ,
Schouten JP, Menko FH (2002) Genomic deletions of MSH2 and MLH1 in
colorectal cancer families detected by a novel mutation detection
approach. Br J Cancer 87: 892–897
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel
R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Klujit I,
Dommering C, Verhoef S, Schouten JP, van’t Veer LJ, Pals G (2003) Large
genomic deletions and duplications in the BRCA1 gene identified by a
novel quantitative method. Cancer Res 63: 1449–1453
Montagna M, Palma MD, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L,
D’Andrea E (2003) Genomic rearrangements account for more than one-
third of the BRCA1 mutations in northern Italian breast/ovarian cancer
families. Hum Mol Genet 12: 1055–1061
Nakagawa H, Hampel H, de la Chapelle A (2003) Identification and
characterisation of genomic rearrangements of MSH2 and MLH1 in
Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 22: 258
Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M,
Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H,
Klijn JG, Vasen HF, Cornelisse CJ, van’t Veer LJ, Bakker E, van Ommen
GJ, Devilee P (1997) BRCA1 genomic deletions are major founder
mutations in Dutch breast cancer patients. Nat Genet 17: 341–345
Plummer SJ, Anton-Culver H, Webster L, Noble B, Liao S, Kennedy A,
Belinson J, Casey G (1995) Detection of BRCA1 mutations by the protein
truncation test. Hum Mol Genet 4: 1989–1991
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F,
Pals G (2002) Relative quantification of 40 nucleic acid sequences by
multiplex ligation-dependant probe amplification. Nucleic Acid Res
30: e57
Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L,
Hodgson S, Thomas HJ, Neale K, Phillips RK, Farrington SM,
Dunlop MG, Mueller HJ, Bisgaard ML, Bulow S, Fidalgo P,
Albuquerque C, Scarano MI, Bodmer W, Tomlinson IP, Heinimann K
(2002) Whole-gene APC deletions cause classical familial
adenomatous polyposis, but not attenuated polyposis or
‘multiple’ colorectal adenomas. Proc Natl Acad Sci USA 99:
2954–2958
Taylor F, Charlton RS, Burn J, Sheridan E, Taylor GR (2003) Genomic
deletions in MSH2 or MLH1 are a frequent cause of hereditary non-
polyposis colorectal cancer: identification of novel and recurrent
deletions by MLPA. Hum Mutat 22: 428–433
Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen
P, Nakagawa H, Geugien M, Jaghmohan-Changur S, Breukel C,
Meijers-Heijboer H, Morreau H, van Puijenbroek M, Burn J, Coronel S,
Kinarski Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT,
Fodde R (2003) Molecular analysis of hereditary nonpolyposis colorectal
cancer in the United States: high mutation detection rate among
clinically selected families and characterisation of an American
founder genomic deletion of the MSH2 gene. Am J Hum Genet 72:
1088–1100
Wang Y, Friedl W, Lamberti C, Jungck M, Mathiak M, Pagenstecher C,
Propping P, Mangold E (2003) Hereditary nonpolyposis colorectal
cancer: frequent occurrence of large genomic deletions in MSH2 and
MLH1 genes. Int J Cancer 103: 636–641
Dosage analysis of cancer predisposition genes by MLPA
DJ Bunyan et al
1159
British Journal of Cancer (2004) 91(6), 1155–1159 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s